TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling
暂无分享,去创建一个
G. Inman | N. Morrell | J. Bradley | J. Deighton | A. Rana | M. Nikolić | B. Dunmore | R. Al‐Lamki | M. Southwood | P. Upton | B. Herrera | L. Long | Xudong Yang | A. Crosby | Liam A. Hurst | L. Hurst | Amer A. Rana
[1] Q. Wang,et al. Preventive and remedial application of etanercept attenuate monocrotaline‐induced pulmonary arterial hypertension , 2016, International journal of rheumatic diseases.
[2] Yan-ting Zhu,et al. Inhibition of Notch3 prevents monocrotaline-induced pulmonary arterial hypertension , 2015, Experimental Lung Research.
[3] A. Harris,et al. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.
[4] A. Bullock,et al. Small Molecules Dorsomorphin and LDN-193189 Inhibit Myostatin/GDF8 Signaling and Promote Functional Myoblast Differentiation* , 2014, The Journal of Biological Chemistry.
[5] P. Sarnow,et al. Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension , 2014, The Journal of experimental medicine.
[6] Wei Wang,et al. Soluble Jagged1 Inhibits Pulmonary Hypertension by Attenuating Notch Signaling , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[7] H. Jo,et al. Anti-Inflammatory and Antiatherogenic Role of BMP Receptor II in Endothelial Cells , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[8] C. Piantadosi,et al. CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension. , 2013, American journal of respiratory cell and molecular biology.
[9] A. Bullock,et al. A New Class of Small Molecule Inhibitor of BMP Signaling , 2013, PloS one.
[10] K. Horiuchi,et al. Systemic Overexpression of TNFα-converting Enzyme Does Not Lead to Enhanced Shedding Activity In Vivo , 2013, PloS one.
[11] Zhaohua Zhang,et al. Mesenchymal stem cell prevention of vascular remodeling in high flow-induced pulmonary hypertension through a paracrine mechanism. , 2012, International immunopharmacology.
[12] J. Ge,et al. Atorvastatin prevents dehydromonocrotaline-induced pulmonary hypertension in beagles , 2012, Experimental lung research.
[13] W. Ouwehand,et al. Cross-domain inhibition of TACE ectodomain , 2011, Proceedings of the National Academy of Sciences.
[14] Huai-liang Wang,et al. Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats , 2011, Acta Pharmacologica Sinica.
[15] R. Trembath,et al. Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension , 2010, Circulation.
[16] H. Verspaget,et al. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. , 2010, Cancer research.
[17] N. Voelkel,et al. Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension , 2010, Circulation.
[18] Samy Lamouille,et al. TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling. , 2009, Molecular cell.
[19] R. Trembath,et al. Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial Cells* , 2009, The Journal of Biological Chemistry.
[20] M. Humbert,et al. Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension , 2009, European Respiratory Journal.
[21] N. Morrell,et al. Altered Bone Morphogenetic Protein and Transforming Growth Factor-β Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease , 2009, Circulation.
[22] R. Trembath,et al. Mutations in Bone Morphogenetic Protein Type II Receptor Cause Dysregulation of Id Gene Expression in Pulmonary Artery Smooth Muscle Cells: Implications for Familial Pulmonary Arterial Hypertension , 2008, Circulation research.
[23] Christopher C W Hughes,et al. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. , 2008, Blood.
[24] D. Despres,et al. Notch2 is required for the proliferation of cardiac neural crest‐derived smooth muscle cells , 2008, Developmental dynamics : an official publication of the American Association of Anatomists.
[25] A. Kurisaki,et al. Activin induces long-lasting N-methyl-d-aspartate receptor activation via scaffolding PDZ protein activin receptor interacting protein 1 , 2008, Neuroscience.
[26] H. Beppu,et al. Bone Morphogenetic Protein (BMP) Type II Receptor Is Required for BMP-mediated Growth Arrest and Differentiation in Pulmonary Artery Smooth Muscle Cells* , 2008, Journal of Biological Chemistry.
[27] R. Trembath,et al. Functional Characterization of Bone Morphogenetic Protein Binding Sites and Smad1/5 Activation in Human Vascular Cells , 2008, Molecular Pharmacology.
[28] R. Trembath,et al. Regulation of bone morphogenetic protein signalling in human pulmonary vascular development , 2008, The Journal of pathology.
[29] E. Gherardi,et al. Eotaxin-1/CC Chemokine Ligand 11: A Novel Eosinophil Survival Factor Secreted by Human Pulmonary Artery Endothelial Cells1 , 2007, The Journal of Immunology.
[30] M. Humbert,et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. , 2007, Human pathology.
[31] W. Seeger,et al. Dysregulated Bone Morphogenetic Protein Signaling in Monocrotaline-Induced Pulmonary Arterial Hypertension , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[32] L. David,et al. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. , 2007, Blood.
[33] R. Tuder,et al. Pathology of pulmonary hypertension. , 2007, Clinics in chest medicine.
[34] L. Lind,et al. Etanercept reduces late endotoxin-induced pulmonary hypertension in the pig. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[35] H. Ishibashi-Ueda,et al. Increased plasma monocyte chemoattractant protein‐1 level in idiopathic pulmonary arterial hypertension , 2006, Respirology.
[36] P. Vandenabeele,et al. TNFR1‐ and TNFR2‐mediated signaling pathways in human kidney are cell type‐specific and differentially contribute to renal injury , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[37] J. Loscalzo,et al. Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-Mutant Mice , 2005, Circulation.
[38] J. Knowles,et al. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. , 2005, American journal of respiratory cell and molecular biology.
[39] H. Beppu,et al. Bone Morphogenetic Protein (BMP) Type II Receptor Deletion Reveals BMP Ligand-specific Gain of Signaling in Pulmonary Artery Smooth Muscle Cells* , 2005, Journal of Biological Chemistry.
[40] N. Rudarakanchana,et al. Dysfunctional Smad Signaling Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial Pulmonary Arterial Hypertension , 2005, Circulation research.
[41] M. Lambert,et al. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. , 2005, Combinatorial chemistry & high throughput screening.
[42] K. Miyazono,et al. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[43] B. Klonjkowski,et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. , 2004, Genes & development.
[44] S. Dehm,et al. SRC gene expression in human cancer: the role of transcriptional activation. , 2004, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[45] J. Arribas,et al. The Shedding of Betaglycan Is Regulated by Pervanadate and Mediated by Membrane Type Matrix Metalloprotease-1* , 2004, Journal of Biological Chemistry.
[46] Ying E. Zhang,et al. Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.
[47] T. Takizawa,et al. Enhanced gene activation by Notch and BMP signaling cross-talk. , 2003, Nucleic acids research.
[48] Wenli Wang,et al. Determinants of Notch-3 Receptor Expression and Signaling in Vascular Smooth Muscle Cells: Implications in Cell-Cycle Regulation , 2002, Circulation research.
[49] M. Goumans,et al. Stimulation of Id1 Expression by Bone Morphogenetic Protein Is Sufficient and Necessary for Bone Morphogenetic Protein–Induced Activation of Endothelial Cells , 2002, Circulation.
[50] N. Rudarakanchana,et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. , 2002, Human molecular genetics.
[51] R. Trembath,et al. Primary Pulmonary Hypertension Is Associated With Reduced Pulmonary Vascular Expression of Type II Bone Morphogenetic Protein Receptor , 2002, Circulation.
[52] S. Hodge,et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.
[53] R. Trembath,et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.
[54] A Cumano,et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. , 2000, Molecular cell.
[55] J. R. Coleman,et al. Mutation in ankyrin repeats of the mouse Notch2 gene induces early embryonic lethality. , 1999, Development.
[56] B. Groves,et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.
[57] W. Chung,et al. Genetics and genomics of pulmonary arterial hypertension. , 2013, Journal of the American College of Cardiology.
[58] K. Miyazono,et al. Bone morphogenetic protein receptors and signal transduction. , 2010, Journal of biochemistry.
[59] V. Salih,et al. Bone morphogenetic protein receptors and bone morphogenetic protein signaling are controlled by tumor necrosis factor-alpha in human bone cells. , 2006, The international journal of biochemistry & cell biology.
[60] R. Derynck,et al. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. , 2003, Nature.
[61] M. Fujita,et al. Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. , 2001, American journal of physiology. Lung cellular and molecular physiology.
[62] M. Humbert,et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. , 2001, American journal of human genetics.
[63] J. Inman,et al. Bmc Cell Biology a Rapid and Sensitive Bioassay for the Simultaneous Measurement of Multiple Bone Morphogenetic Proteins. Identification and Quantification of Bmp4, Bmp6 and Bmp9 in Bovine and Human Serum , 2022 .